KYORIN Holdings Inc (4569) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
Apr 26,2022: Kyorin Holdings Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2022
Feb 04,2022: Kyorin Holdings announces Financial Results for the 3rd Quarter of the Fiscal Year Ending March 2022
May 11,2021: Kyorin Remedio Notice regarding changes in officers
Note: Some sections may be missing if data is unavailable for the company.
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
KYORIN Holdings Inc (Kyorin) is a holding company that controls, administers and supports its group companies that conduct various businesses by holding the shares of those companies. The company through its subsidiaries carries out the discovery, development, manufacturing and sale of pharmaceuticals including new ethical drugs, generic drugs and the over the counter (OTC) drugs, diagnostics, reagents, intermediates, diagnostics, industrial chemicals and other products. The company markets its product under Kipres, Mucodyne, Pentasa, Uritos, Ketas, Flutiform, Milton, Rubysta and other brands. The company operates is business through its subsidiaries including KYORIN Pharmaceutical Co Ltd, KYORIN Rimedio Co Ltd and KYORIN Pharmaceutical Group Facilities Co Ltd in Japan. Kyorin is headquartered in Tokyo, Japan.KYORIN Holdings Inc Key Recent Developments
May 11,2022: Kyorin Pharmaceutical Co. Notice regarding changes in officersApr 26,2022: Kyorin Holdings Revision of Consolidated Financial Forecasts for Fiscal Year Ended March 31, 2022
Feb 04,2022: Kyorin Holdings announces Financial Results for the 3rd Quarter of the Fiscal Year Ending March 2022
May 11,2021: Kyorin Remedio Notice regarding changes in officers
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.
Table of Contents
Section 1 - About the Company
Section 2 - Company Analysis
Section 3 - Company Financial Ratios
Section 4 - Company’s Lifesciences Financial Deals and Alliances
Section 5 - Company’s Recent Developments
Section 6 - Appendix
List of Tables
List of Figures
Samples
LOADING...
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Torii Pharmaceutical Co Ltd
- Teijin Ltd
- Santen Pharmaceutical Co Ltd
- Nippon Shinyaku Co Ltd
- Mochida Pharmaceutical Co Ltd
- Astellas Pharma Inc